Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD Louie Pasculli, Clayton Mucha, MD

Published Date: 14 Nov 2026

In honor of Veterans Day, Clayton Mucha, DO, neurorehabilitation physiatrist at Burke Rehabilitation in New York, discusses the lasting effects of traumatic brain injury in military personnel.

GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial Isabella Ciccone, MPH

Published Date: 14 Nov 2026

GV101 receives FDA fast track designation for the treatment of Friedreich ataxia, with a phase 2 trial planned to begin enrollment in late 2026.

FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study Isabella Ciccone, MPH

Published Date: 14 Nov 2026

The FDA granted fast track designation to FRP-003, an investigational oral botanical drug candidate for Long COVID, ahead of a planned phase 2 trial evaluating fatigue in approximately 220 adults.

Awareness, Not Access, Remains the Barrier to NF1 Therapy Marco Meglio

Published Date: 14 Nov 2026

At a NeurologyLive Clinical Forum in Phoenix, Kevin J. Bielamowicz, MD, of Arkansas Children’s Hospital, discussed how a lack of adult neuro-oncology infrastructure is shaping how NF1-associated plexiform neurofibromas get recognized, referred, and treated.

Headlining Current Advances and Challenges in Multiple Sclerosis Care Robert Bermel, MD, Louie Pasculli

Published Date: 14 Nov 2026

Robert Bermel, MD, discusses advances in disease-modifying therapies, the challenges of monitoring MS progression, and emerging biomarkers and treatments that may address remaining unmet needs.

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Published Date: 14 Nov 2026

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Knowledge Hub

Oncology

Safety of Radiolabeled Antibody Therapeutics: Unintended Radiation Exposure to Non-Target Organs

A clinical review of non-target organ radiation exposure from radiolabeled antibodies, including mechanisms, risk factors, diagnosis, management, and emerging safety strategies.

Oncology

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

A medical review of bispecific antibody-drug conjugates, including mechanisms, tumor heterogeneity, clinical applications, toxicities, emerging evidence, and future oncology practice.

Oncology

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

A multidisciplinary, evidence-based review of diagnosing and managing cancer recurrence in previously treated anatomical sites, including salvage therapy, reirradiation, systemic treatment, and guideline-informed coordination.

Oncology

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

An evidence-based review of oncology treatment toxicity recognition, diagnosis, management, guideline recommendations, and educational strategies for healthcare professionals.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD Louie Pasculli, Clayton Mucha, MD

GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial Isabella Ciccone, MPH

FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study Isabella Ciccone, MPH

Awareness, Not Access, Remains the Barrier to NF1 Therapy Marco Meglio

Headlining Current Advances and Challenges in Multiple Sclerosis Care Robert Bermel, MD, Louie Pasculli

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Knowledge Hub

Safety of Radiolabeled Antibody Therapeutics: Unintended Radiation Exposure to Non-Target Organs

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

Forecasting Durable Cancer Control Through Tumor Clonal Succession Patterns After Local Therapy

Emerging Trends in Oncology and Precision Medicine

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Understanding the Long-Term Effects of Traumatic Brain Injury in Military Personnel: Clayton Mucha, MD Louie Pasculli, Clayton Mucha, MD

GV101 Gains FDA Fast Track Status for Friedreich Ataxia Ahead of Phase 2 Trial Isabella Ciccone, MPH

FDA Grants Fast Track Status to FRP-003 for Long COVID Ahead of Phase 2 Study Isabella Ciccone, MPH

Awareness, Not Access, Remains the Barrier to NF1 Therapy Marco Meglio

Headlining Current Advances and Challenges in Multiple Sclerosis Care Robert Bermel, MD, Louie Pasculli

Q&A: Healthy Skin Month—What Clinicians Should Watch in Skin Cancer Care

Knowledge Hub

Safety of Radiolabeled Antibody Therapeutics: Unintended Radiation Exposure to Non-Target Organs

Bispecific Antibody-Drug Conjugates for Targeted Elimination of Heterogeneous Tumor Cell Populations

Coordinating Multidisciplinary Decision-Making for Cancer Recurrence Across Previously Treated Anatomical Sites

Teaching Treatment Toxicity Recognition in Oncology: A Clinical and Evidence-Based Review

Digital Cancer Survivorship Record Platforms: Clinical Utility, Governance, and Future Directions

Forecasting Durable Cancer Control Through Tumor Clonal Succession Patterns After Local Therapy

Emerging Trends in Oncology and Precision Medicine

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views